Weight-Loss Medications and Facial Changes: What's Driving Demand

A 2025 report from the consulting firm McKinsey & Company looked at how GLP-1 medications, a class of drugs used for diabetes and weight management, are changing who seeks aesthetic care. Based on a survey of aesthetic providers, it found that many people asking about facial treatment after weight loss had never had aesthetic treatment before, and that loose skin was their main concern. It is an industry report, not a medical study, so it describes trends rather than what treatment works.

Why this was looked at

GLP-1 medications have become widely prescribed in recent years. The report cites prescription growth of roughly 38% per year worldwide between 2022 and 2024. When weight comes off, it comes off everywhere, including the fat pads that give the face its shape. Rapid or large weight loss can leave the face looking hollow, older or tired, and skin may not tighten as quickly as volume is lost. This is sometimes described in the media with catchy nicknames, but it is the same facial change seen with any significant weight loss. Our article on facial hollowing after weight loss explains why it happens.

What the report did

At the end of 2024, the authors surveyed 174 aesthetic providers, including medical spas, dermatology clinics and plastic surgery practices. Providers were asked about patients on these medications who were seeking aesthetic care: their concerns, goals, and spending. The report does not say how providers were chosen or how many were invited, and the answers reflect providers' impressions rather than patient records.

What they found

• Many were new to aesthetics. Providers reported that about 63% of these patients seeking facial treatment had not used aesthetic services before. Around half had never considered it until they lost weight.
• Substantial weight loss was common. About 61% had lost between 11% and 30% of their body weight.
• Skin laxity led the concerns. Loose skin on the face and neck was the top concern, followed by skin quality and facial fullness. Many people had more than one concern.
• Most wanted to look like themselves. Just over half wanted a natural result close to how they looked before losing weight.
• Treatment gaps. Almost a third of providers felt current options do not work as well as they would like for these patients.

The report goes on to make business recommendations for the aesthetics industry. Those are outside the scope of this article and are not relevant to patient decisions.

How strong is this evidence?

This is a market report based on a provider survey. It is useful for seeing broad trends but has important limits. It did not examine patients directly, did not measure facial changes, and did not test whether any treatment helps. The sample was modest and its selection was not described. Statements about how these medications affect skin are based on emerging research the report cites rather than its own data. It also reflects mainly the US market, so it may not mirror what happens in Nova Scotia.

It is also worth noting the source. A consulting firm writes for businesses and investors, so its focus is on demand and market opportunity rather than patient wellbeing. That does not make the survey figures wrong, but it does mean they answer a different question from the ones most patients have, such as "Is treatment safe for me?" or "Will it help?" Those questions need clinical research and an individual assessment.

What it means for you

If you are taking a GLP-1 medication and notice changes in your face, you are not alone, and it is a normal consequence of weight loss rather than a sign that something is wrong. Some practical points:

• Your health comes first. Weight loss can bring real health benefits. Never stop or change a prescribed medication for cosmetic reasons without talking to the doctor who prescribed it.
• Timing matters. While weight is still changing, the face keeps changing too. Many clinicians suggest waiting until weight has been stable for a while before planning volume treatment, so results are not outpaced by further loss.
• Volume and laxity are different problems. Filler or collagen-stimulating injectables can replace some lost volume, but loose skin may respond better to skin-tightening treatments, and significant laxity may need a surgical opinion. Our article on loose skin after weight loss covers the options.
• More is not better. Trying to replace all lost volume with filler can look heavy. A natural result usually involves modest, staged changes.
• General health supports skin. Adequate protein, sun protection and not smoking all support skin quality, particularly during weight loss.

Hair shedding can also follow rapid weight loss, which is covered in our article on hair shedding after rapid weight loss. If shedding is heavy or lasts, see your family doctor to check iron, thyroid and nutrition.

Questions to ask at your consultation

• Is my weight stable enough to plan treatment now, or should I wait?
• Is my main issue lost volume, loose skin, or both?
• What would a modest first step look like?
• Are there any interactions between my medications or health conditions and the treatments you are suggesting?

Frequently asked questions

Do GLP-1 medications damage the skin directly?

Current evidence mainly points to the effects of weight loss itself. Research on direct effects on skin is still emerging, and this report did not study it.

Will my face go back to normal if I regain weight?

Some fullness may return, but repeated weight changes can stretch skin. It is best to plan around a stable weight you can maintain.

Do I need treatment at all?

Not necessarily. Many people adapt to the change, and some prefer to wait and see. Treatment is a personal choice, not a requirement.

If you have noticed facial changes after weight loss and want to understand your options, a consultation at HealthPark Medical Aesthetics can help you weigh timing, choices and realistic expectations.

Source

Jansen L, Peters N, Leclerc O. GLP-1s are boosting demand for medical aesthetics. McKinsey & Company, 2025. Read the report